{"entity":{"id":"nct04785196","kind":"trial","name":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in sarcomas, run by Ascentage Pharma Group Inc., now recruiting.","summary":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04785196 by Ascentage Pharma Group Inc., with 95 participants planned, started 2021-05-26 and due to reach its primary completion in 2026-04. Interventions recorded: APG-115 and Toripalimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04785196","url":"https://clinicaltrials.gov/study/NCT04785196"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04785196","phase":"1/2","setting":"A Phase Ib/II Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","enrolled":95,"outcomes":[]},"route":"/trials/nct04785196/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}